Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
In stock Swipe right to view full table Save over 70%
Patient results on MEDVi's platform are consistent with those findings
Safety monitoring should account for several important risks: Diabetic retinopathy : Patients with existing retinopathy should be monitored closely, particularly if experiencing rapid improvements in blood glucose levels, as this can temporarily worsen eye complications
(NIHSS/24h Intervention = 4.38 0.99 vs NIHSS/24h control = 6.82 1.24, p = 0.134, NIHSS/2weeks Intervention = 2.94 0.70 vs NIHSS/2weeks control = 5.93 1.36, p = 0.05, NIHSS/1month Intervention = 2.22 0.56 vs NIHSS/1month control = 6 1.63, p = 0.02, and NIHSS/3months Intervention = 1.83 0.51 vs NIHSS/3months control = 3.53 0.71, p = 0.057)
Berberine may interact with antidiabetic medications, anticoagulants, and drugs metabolised by CYP450 enzymes
Increasing the dosage could help
US$ 21.64
US$ 22.10
US$ 23.01
US$ 21.37
US$ 29.75
US$ 21.38
US$ 26.71
US$ 21.11
US$ 29.38
